The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 16, 2021
Filed:
Mar. 01, 2017
Applicant:
Propellon Therapeutics Inc., Toronto, CA;
Inventors:
Rima Al-Awar, Toronto, CA;
Carlos Armando Zepeda-Velazquez, Mississauga, CA;
Gennady Poda, Toronto, CA;
Methvin Isaac, Brampton, CA;
David Uehling, Toronto, CA;
Brian Wilson, Mississauga, CA;
Babu Joseph, Oakville, CA;
Yong Liu, Oakville, CA;
Pandiaraju Subramanian, Oakville, CA;
Ahmed Mamai, Mississauga, CA;
Assignee:
Propellon Therapeutics Inc., Toronto, CA;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/167 (2006.01); C07C 233/57 (2006.01); C07C 233/64 (2006.01); C07D 413/12 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 401/14 (2006.01); C07D 491/08 (2006.01); C07D 237/14 (2006.01); C07D 213/81 (2006.01); C07D 295/135 (2006.01); C07D 405/14 (2006.01); A61K 45/06 (2006.01); C07D 213/82 (2006.01); C07D 235/08 (2006.01); C07D 235/24 (2006.01); C07D 237/24 (2006.01); C07D 413/10 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
C07D 413/12 (2013.01); A61K 45/06 (2013.01); C07D 213/81 (2013.01); C07D 213/82 (2013.01); C07D 235/08 (2013.01); C07D 235/24 (2013.01); C07D 237/14 (2013.01); C07D 237/24 (2013.01); C07D 295/135 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 413/10 (2013.01); C07D 471/04 (2013.01); C07D 491/08 (2013.01);
Abstract
The present application is directed to compounds of Formula I: compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.